SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) [Yahoo! Finance]
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Scynexis: Update Following Restructuring Of GSK Deal [Seeking Alpha]
SCYNEXIS, Inc. (NASDAQ: SCYX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]